Eur Rev Med Pharmacol Sci 2026; 30 (3): 94-94
DOI: 10.26355/eurrev_202603_37717

Retraction Note: Expression of miR-1294 is downregulated and predicts a poor prognosis in gastric cancer

Y.-X. Shi, B.-L. Ye, B.-R. Hu, X.-J. Ruan

Department of General Surgery, the First Affiliated Hospital of Wenzhou Medical University, China


The article “Expression of miR-1294 is downregulated and predicts a poor prognosis in gastric cancer” by Y.-X. Shi, B.-L. Ye, B.-R. Hu, X.-J. Ruan, published in Eur Rev Med Pharmacol Sci 2018; 22 (17): 5525-5530–DOI: 10.26355/eurrev_201809_15813–PMID: 30229824, has been retracted in accordance with the Publisher and the Editor in Chief.

Following a previously published Expression of Concern, the Editor-in-Chief and the Publisher have completed an investigation into the issues raised in relation to this article.

The investigation confirmed concerns regarding non-verifiable nucleotide sequence reagents and the use of inadequately authenticated cell lines, which undermine the reliability of the findings reported.

The authors did not respond to correspondence regarding these concerns.

The Editor-in-Chief and the Publisher have therefore decided to retract this article.

This article has been retracted. The Publisher apologizes for any inconvenience this may cause.
Free PDF Download

To cite this article

Y.-X. Shi, B.-L. Ye, B.-R. Hu, X.-J. Ruan
Retraction Note: Expression of miR-1294 is downregulated and predicts a poor prognosis in gastric cancer

Eur Rev Med Pharmacol Sci
Year: 2026
Vol. 30 - N. 3
Pages: 94-94
DOI: 10.26355/eurrev_202603_37717

Publication History

Published online: 31 Mar 2026